p53 activity is essential for normal development in Xenopus

Current Biology

Volumn 7, Issue 10, 1997, Pages 747-757

  Wallingford, John B ^a   Seufert, Daniel W ^a   Virta, Valerie C ^a   Vize, Peter D ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0031260564     PISSN: 09609822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9822(06)00333-2     Document Type: Article

References (72)

1. Jenkins JR, Rudge K, Currie GA: Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53. Nature 1984, 312:651-654.
2. Parada LF, Land H, Weinberg RA, Wolf D, Rotter V: Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature 1984, 312:649-651.
3. Eliyahu D, Michalovitz D, Oren M: Overproduction of p53 antigen makes established cells highly tumorigenic. Nature 1985, 316:158-160.
4. Finlay CA, Hinds PW, Levine AJ: The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989, 57:1083-1093.
5. Donehower LA, Bradley A: The tumor suppressor p53. Biochim Biophys Acta 1993, 1155:181-205.
6. Gottlieb T, Oren M: p53 in growth control and neoplasia. Biochim Biophys Acta 1996, 1287:77-102.
7. Haffner R, Oren M: Biochemical properties and biological effects of p53. Curr Opin Genet Dev 1995, 5:84-90.
8. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996, 379:88-91.
9. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr., Butel JS, Bradley A: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992, 356:215-221.
10. Armstrong J, Kaufman A, Harrison D, Clarke A: High-frequency developmental abnormalities in p53-deficient mice. Curr Biol 1995, 5:931-936.
11. Sah VP, Attardi LD, Mulligan GJ, William BO, Bronson RT, Jacks T: A subset of p53 deficient mice exhibit exencephally. Nature Genet 1995, 10:175-180.
12. Schmid P, Lorenz A, Hameister H, Montenarh M: Expression of p53 during mouse embryogenesis. Development 1991, 113:857-865.
13. Komarova EA, Chernov MV, Franks R, Wnag K, Armin G, Zelnick CR et al.: Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines readiation and drug sensitivity in vivo. EMBO J 1997, 16:1391-1400.
14. Gottleib E, Haffner R, King A, Asher G, Gruss P, Lonai P, Oren M. Transgenic mouse model for studying the transcriptional activity of the p53 protein: age- and tissue-dependent changes in radiation-induced activation during embryogenesis. EMBO J 1997, 16:1381-1390.
15. MacCallum DE, Hupp TR, Midgley CA, Stuart D, Campbell SJ, Harper A et al.: The p53 response to ionising radiation in adult and developing murine tissues. Oncogene 1996, 13:2575-2587.
16. Montes de Oca Luna R, Wagner DS, Lozano G: Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995, 378:203-206.
17. Jones SN, Roe AE, Donehower LA, Bradley A: Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995, 378:206-208.
18. Harvey M, Vogel H, Morris D, Bradley A, Bernstein A, Donehower LA: A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nature Genetics 1995, 9:305-311.
19. Shalusky G, Goldfinger N, Peled A, Rotter V: Involvement of wild-type p53 in pre-B cell differentiation in vitro. Proc Natl Acad Sci USA 1991, 88:8982-8986.
20. Soddu S, Blandino G, Scardigli R, Coen S, Marchetti A, Rizzo MG, Bossi G, Cimino L, Crescenzi M, Sacchi A: Interference with p53 protein inhibits hematopoietic and muscle differentiation. EMBO J 1996, 134:193-204.
21. Eizenberg O, Faber-Elman A, Gottleib E, Oren M, Rotter V, Schwartz M: p53 plays a regulatory role in differentiation and apoptosis of central nervous system-associated cells. Mol Cell Biol 1996, 16:5178-5185.
22. Ferreira A, Kosik KS: Accelerated neuronal differentiation induced by p53 suppression. J Cell Sci 1996, 109:1509-1516.
23. Hall PA, Lane DP: Tumor suppressors: a developing role for p53? Curr Biol 1997, 7:R14-R147.
24. Rotter V, Aloni-Grinstein R, Schwartz D, Elkind NB, Simons A, Wolkowicz R et al.: Does wild-type p53 play a role in normal cell differentiation? Semin Cancer Biol 1994, 5:229-236.
25. Cox L, Midgley C, Lane D: Xenopus p53 is biochemically similar to the human tumour suppressor protein p53 and is induced upon DNA damage in somatic cells. Oncogene 1994, 9:2951-2959.
26. Hoever M, Clement JH, Wedlich D, Montenarh M, Knochel W: Overexpression of wild-type p53 interferes with normal development in Xenopus laevis embryos. Oncogene 1994, 9:109-120.
27. Tchang F, Gusse M, Soussi T and Mechali M: Stabilization and expression of high levels of p53 during early development in Xenopus laevis. Dev Biol 1993, 159:163-172.
28. Hemmatti-Brivanlou A, Melton DA: A truncated activin receptor inhibits mesoderm induction and formation of axial structures in Xenopus embryos. Nature 1992, 359:609-614.
29. Levine E, Lee CH, Kintner C, Gumbiner BM: Selective disruption of E-cadherin function in early Xenopus embryos by a dominant negative mutant. Development 1994, 120:901-909.
30. Molenaar M, van de Wetering M, oosterwgel M, Peterson-Maduro J, Godsave S, Korinek V et al.: XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos. Cell 1996, 86:391-399.
31. Dong Z, Xu RH, Kim J, Zhan SN, Ma WY, Colburn NH, Kung H: AP-1/jun is required for early Xenopus development and mediates mesoderm induction by fibroblast growth factor but not by activin. J Biol Chem 1996, 271:9942-9946.
32. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM et al.: Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1 989, 244:217-221.
33. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K et al.: Mutations in the p53 gene occur in diverse human tumor types. Nature 1989, 342:705-708.
34. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M et al..: Gain-of-function mutations in p53. Nature Genet 1993, 4:42-46.
35. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, Pavletich NP: Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996, 274:948-953.
36. Momand J, Zambetti GP, Olson DC, George D, Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69:1237-1245.
37. Haupt Y, Mara R, Kazaz A, Oren, M: Mdm2 promotes rapid degradation of p53. Nature 1997, 387:296-299.
38. Kubbutat MHG, Jones SN, Vousden KH: Regulation of p53 stability by Mdm2. Nature 1997, 387:299-303.
39. Sun Y, Dong Z, Nakamura K, Colburn N: Dosage dependent dominance over wild-type p53 of a mutant p53 isolated from nasopharyngeal carcinoma. FASEB J 1994, 7:944-950.
40. Vize PD, Melton DA, Hemmati-Brivanlou A, Harland R: Assays for gene function in developing Xenopus embryos. Meth Cell Biol 1991, 36:367-387
41. Harland RM, Misher L: Stability of RNA in developing Xenopus embryos and identification of a destabilizing sequence in TFIIIA RNA. Development 1988, 102:837-852.
42. Lassus P, Ferlin M, Piette J, Hibner U: Anti-apoptotic activity of low levels of wild-type p53. EMBO J 1996, 15:4566-4573.
43. Chen X, Ko LJ, Jayaraman L, Prives C: p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 1996, 10:2438-2451.
44. Vleminckx K, Wong E, Guger K, Rubinfeld B, Polakis P, Gumbiner B: Adenomatous polyposis coli tumor suppressor protein has signalling activity in Xenopus laevis embryos resulting in the induction of an ectopic dorsoanterior axis. J Cell Biol 1997, 136:411-420.
45. Whitman M, Melton D: Involvement of p21 ras in Xenopus mesoderm induction. Nature 1992, 357:252-254.
46. Whitman M, Melton D: Induction of mesoderm by a viral oncogene in early Xenopus embryos. Science 1989, 244:803-806.
47. Hartley R, Rempel R, Mailer J: In vivo regulation of the early embryonic cell cycle in Xenopus. Dev Biol 1996, 173:408-419.
48. Sakaguchi DS, Moeller JF, Coffman CR, Gallenson N, Harris WA: Growth cone interactions with a glial cell line from embryonic Xenopus retina. Dev Biol 1989, 134:158-174.
49. Kintner C, Brockes J: Monoclonal antibodies identify blastemal cells derived from differentiating muscle in newt limb regeneration. Nature 1984, 308:67-69.
50. Godfrey LA, Kopp JB, Eckhaus M, Palino J, Owens J, Varmus HE: Wild-type p53 transgenic mice exhibit altered differentiation of the ureteric bud and possess small kidneys. Genes Dev 1996, 10:836-850.
51. Maheswaran S, Park S, Bernard A, Morris J, Rauscher F, Hill D, Haber DA: Physical and functional interaction between the WT1 and p53 proteins. Proc Natl Acad Sci USA 1993, 90:5100-5104.
52. Vize PD, Jones EA, Pfister R: Development of the Xenopus pronephric system. Dev Biol 1995, 171:531-540.
53. Wang Y, Farmer G, Soussi T, Prives C: Xenopus laevis p53 protein: sequence-specific DNA binding, transcriptional regulation and oligomerization are evolutionarily conserved. Oncogene 1995, 19:779-784.
54. Olson DC, Levine AJ: The properties of p53 proteins selected for the loss of suppression of transformation. Cell Growth Diff 1994, 5:61-71.
55. Blagosklonny MV, Toretsky J, Neckers L: Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene 1995, 11:933-939.
56. Oren M, Reich NC, Levine AJ: Regulation of the cellular p53 tumor antigen in teratocarcinoma cells and their differentiated progeny. Mol Cell Biol 1982, 2:443-449.
57. Cho Y, Gorina S, Jeffrey P, Pavletich N: Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994, 265:346-355.
58. Newport J, Kirschner M: A major developmental transition in early Xenopus embryos: I. characterization and timing of cellular changes at the midblastula stage. Cell 1982, 30:675-686.
59. Newport J, Kirschner M: A major developmental transition in early Xenopus embryos: II. Control of the onset of transcription. Cell 1982, 30:687-696.
60. Krieg PA, Varnum SM, Wormington WM, Melton DA: The mRNA encoding elongation factor alpha (EF1 -alpha) is a major transcript at the mid-blastula transition in Xenopus. Dev Biol 1989, 133:93-100.
61. Smith JC, Price BM, Green JB, Weigel D, Hermann BG: Expression of a Xenopus homolog of Brachyury (T) is an immediate-early response to mesoderm induction. Cell 1991, 67:79-87.
62. Cho KW, Blumberg B, Steinbresser H, DeRobertis EM: Molecular nature of Spemann's organizer: the role of the Xenopus homeobox gene goosecoid. Cell 1991, 67:1111-1120.
63. Howe JA, Howell M, Hunt T, Newport JW: Identification of a novel developmental timer regulating the stability of embryonic cyclin A and a new somatic A-type cyclin at gastrulation. Genes Dev 1995, 9:1164-1176.
64. Hupp TR, Meek DW, Midgley CA, Lane DP: Regulation of the specific DNA binding function of p53. Cell 1992, 71:875-886.
65. Lutzker SG, Levine AJ: A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nature Med 1996, 2:804-810.
66. Rudnicki MA, Schnegelsberg PN, Stead RH, Braun T, Arnold HH, Jaenisch R: MyoD or Myf-5 is required for the formation of skeletal muscle. Cell 1993, 75:1351-1359.
67. Matzuk MM, Kumar TR, Vassalli A, Bickenbach JR, Roop DR, Jaenisch R, Bradley A: Functional analysis of activins during mammalian development. Nature 1995, 374:354-356.
68. Matzuk MM, Kumar TR, Bradley A: Different phenotypes for mice deficient in either activins or activin recptor type II. Nature 1995, 374:356-360.
69. Krieg PA Melton DA: Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs. Nucleic Acids Res 1984, 12:7057-7070.
70. Nieuwkoop P, Faber J: Normal Table of Xenopus laevis (Daudin). New York: Garland; 1994.
71. Carroll TJ, Vize PD: Wilms tumor suppressor gene is involved in the development of disparate kidney forms: evidence from expression in the Xenopus pronephros. Dev Dynamics 1996, 206:131-138.
72. Dale L, Slack JM: Fate map for the 32-cell stage of Xenopus laevis. Development 1987 99:527-551.